<p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2021/11/cassava-sciences.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2021/11/cassava-sciences.jpg"/></p>
<p>Cassava Sciences（纳斯达克：SAVA）股价已经跌至谷底。曾经是一只备受追捧的股票，今年已经下跌超过 45%，从历史最高点下跌超过 90%，市值超过 5.3 亿美元。在股价飙升时，该公司估值曾超过 74 亿美元。</p>
<h2>跌入谷底的继续</h2>
<p>Cassava Sciences 是阿尔茨海默病研究领域的领先公司之一，在交易员中备受瞩目。随着 FDA 批准白光公司的 aducanumab 并开始以每年 26500 美元的价格销售，该公司在 2021 年人气飙升。</p>
<p>然而，最近，尽管阿尔茨海默病行业仍然强劲，但有迹象表明其复杂性使许多投资者退缩。今年早些时候，白光公司宣布将重新调整在该行业的资源，停止开发和商业化 ADUHELM。</p>
<p>Cassava Sciences 希望凭借其名为 Simufilam 的药物成为该行业的主要参与者。该公司希望该药物最终能够获得 FDA 的授权。</p>
<p>考虑到阿尔茨海默病影响美国和全球超过 500 万人，这是一个庞大的行业。</p>
<p>然而，该公司在过去几年中承受了巨大压力，这导致股价暴跌。尽管 Simufilam 处于第三阶段试验中，但人们对其数据完整性表示担忧。</p>
<h2>王浩岩问题持续</h2>
<p>这些担忧在上周加剧，当时前科学顾问王浩岩被指控欺诈美国国立卫生研究院（NIH）。当局称他在 2017 年至 2018 年之间发送了拨款申请并获得了 1600 万美元的拨款。他将这些拨款归为自己和 Cassava Sciences。</p>
<p>王浩岩长期以来一直备受关注。在《纽约时报》的一篇报道中，对他的工作进行的调查显示，他因未能保留或提供原始数据而被指责鲁莽。</p>
<p>新的诉讼意味着该公司及其试验可能在未来几个月内接受更多审查。此外，阿尔茨海默病是一种治疗难度极大的疾病，这一点由许多失败的测试所证明。</p>
<p>此外，有关数据管理不当和公司缺乏原始数据的指控。一些分析师也质疑该公司的药物是否有效，一些人指出王浩岩曾篡改结果。</p>
<p>最近的财务结果显示，Cassava Sciences 的业务出现了 1990 万美元的营业亏损。其中大部分资金用于研发。其净利润超过 2500 万美元，得益于权证负债公允价值的增值。</p>
<p>该公司还拥有强劲的资产负债表，使其无需筹集资金即可运营。其现金及等价物超过 1200 万美元。这意味着该公司可能需要在 2025 年或 2026 年筹集资金。</p>
<p>尽管如此，我认为 Cassava Sciences 是一家高风险公司，其 Simufilam 药物面临着重大风险。</p>
<h2>Cassava Sciences 股价分析</h2>
<p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2024/07/Cassava-Sciences-stock-1024x570.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2024/07/Cassava-Sciences-stock-1024x570.png"/></p>
<p>TradingView 提供的 SAVA 图表</p>
<p>周线图显示，SAVA 股价在过去几年中一路下跌。上周五，股价跌破了 12.33 美元的关键支撑位，创下 2023 年 10 月和 2022 年 7 月的最低点。</p>
<p>Cassava Sciences 的股价一直低于 50 周和 100 周指数移动平均线（EMA）。因此，股价可能会继续下跌，卖方将瞄准 10 美元的关键支撑位。这意味着它可能会从当前水平下跌约 20%。跌破该点可能会下跌至 6.40 美元的关键点。</p>
<p>本文最初发表于 Invezz，转载请注明出处。</p>

SAVA

<p>今年以来，Cassava Sciences（纳斯达克股票代码：SAVA）股价已下跌超过 45%，距离历史最高点已下跌超过 90%。该公司的药物 Simufilam 正在进行第三阶段临床试验，但面临数据完整性问题和操纵指控的担忧。最近针对一位前科学顾问的欺诈指控进一步引起了审查。尽管财务状况强劲且未来可能需要筹集资金，但 Cassava Sciences 仍然是一项高风险投资</p>

<p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2021/11/cassava-sciences.jpg" alt="" original-src="https://invezz.com/wp-content/uploads/2021/11/cassava-sciences.jpg"/></p>
<p>Cassava Sciences (NASDAQ: SAVA) stock price has become a fallen angel. Once a high popular stock, it has crashed by over 45% this year and by more than 90% from its all-time high, giving it a market cap of over $530 million. At its peak, the company had a valuation of over $7.4 billion.</p>
<div class="lb-trans"><p>Cassava Sciences（纳斯达克：SAVA）股价已经跌至谷底。曾经是一只备受追捧的股票，今年已经下跌超过 45%，从历史最高点下跌超过 90%，市值超过 5.3 亿美元。在股价飙升时，该公司估值曾超过 74 亿美元。</p>
</div><h2>Fall from grace continues</h2>
<div class="lb-trans"><h2>跌入谷底的继续</h2>
</div><p>Cassava Sciences, a leading company in Alzheimer’s research, was one of the hottest companies among traders. Its popularity soared in 2021 as most investors focused on Alzheimer after the FDA approved Biogen’s aducanumab, which it started selling at $26,500 per year.</p>
<div class="lb-trans"><p>Cassava Sciences 是阿尔茨海默病研究领域的领先公司之一，在交易员中备受瞩目。随着 FDA 批准白光公司的 aducanumab 并开始以每年 26500 美元的价格销售，该公司在 2021 年人气飙升。</p>
</div><p>Recently, however, while the Alzheimer’s industry is still robust, there are signs that its complexity has made many investors to pull back. Earlier this year, Biogen announced that it would reprioritise its resources in the industry by discontinuing the development and commercialisation of ADUHELM.</p>
<div class="lb-trans"><p>然而，最近，尽管阿尔茨海默病行业仍然强劲，但有迹象表明其复杂性使许多投资者退缩。今年早些时候，白光公司宣布将重新调整在该行业的资源，停止开发和商业化 ADUHELM。</p>
</div><p>Cassava Sciences is hoping to become a major player in the industry, thanks to its drug, which is known as Simufilam. The company hopes that the drug will ultimately receive authorisation by the FDA.</p>
<div class="lb-trans"><p>Cassava Sciences 希望凭借其名为 Simufilam 的药物成为该行业的主要参与者。该公司希望该药物最终能够获得 FDA 的授权。</p>
</div><p>Alzheimer’s is a big industry considering that it affects over 5 million people in the United States and around the world.</p>
<div class="lb-trans"><p>考虑到阿尔茨海默病影响美国和全球超过 500 万人，这是一个庞大的行业。</p>
</div><p>However, the company has come under intense pressure in the past few years, which has contributed to the stock’s collapse. While simufilam is in the third phase of trial, there have been concerns about its data integrity.</p>
<div class="lb-trans"><p>然而，该公司在过去几年中承受了巨大压力，这导致股价暴跌。尽管 Simufilam 处于第三阶段试验中，但人们对其数据完整性表示担忧。</p>
</div><h2>Hoau-Yan Wang problems continue</h2>
<div class="lb-trans"><h2>王浩岩问题持续</h2>
</div><p>These concerns accelerated on Friday when Hoau-Yan Wang, a former scientific advisor was accused of defauding the National Institutes of Health (NIH). Authorities alleged that he defrauded the government by sending grant applications and receiving $16 million in grants between 2017 and 2018. He took these grants on his behalf and that of Cassava Sciences.</p>
<div class="lb-trans"><p>这些担忧在上周加剧，当时前科学顾问王浩岩被指控欺诈美国国立卫生研究院（NIH）。当局称他在 2017 年至 2018 年之间发送了拨款申请并获得了 1600 万美元的拨款。他将这些拨款归为自己和 Cassava Sciences。</p>
</div><p>Wang has been in the spotlight for a long time. In this New York Times report, an investigation into his work showed that he was reckless for failing to keep or provide original data.</p>
<div class="lb-trans"><p>王浩岩长期以来一直备受关注。在《纽约时报》的一篇报道中，对他的工作进行的调查显示，他因未能保留或提供原始数据而被指责鲁莽。</p>
</div><p>The new filing means that the company and its trial will likely get into more scrutiny in the coming months. Besides, Alzheimer’s is one of the toughest diseases to treat, as evidenced by the many failed tests.</p>
<div class="lb-trans"><p>新的诉讼意味着该公司及其试验可能在未来几个月内接受更多审查。此外，阿尔茨海默病是一种治疗难度极大的疾病，这一点由许多失败的测试所证明。</p>
</div><p>Also, there have been allegations of data mismanagement and the lack of raw data in the company. Some analysts also question whether the company’s drug is effective after all, with some noting that Wang had manipulated the results.</p>
<div class="lb-trans"><p>此外，有关数据管理不当和公司缺乏原始数据的指控。一些分析师也质疑该公司的药物是否有效，一些人指出王浩岩曾篡改结果。</p>
</div><p>The most recent financial results showed that Cassava Sciences’ business had an operating loss of $19.9 million. Most of these funds went to researcg and development. Its net profit came in at over $25 million, thanks to the gain in fair value of warrant liabilities.</p>
<div class="lb-trans"><p>最近的财务结果显示，Cassava Sciences 的业务出现了 1990 万美元的营业亏损。其中大部分资金用于研发。其净利润超过 2500 万美元，得益于权证负债公允价值的增值。</p>
</div><p>The company also has a strong balance sheet that gives it room to operate without the need to raise cash. It had over $12 million in cash and equivalents. This means that the company will likely need to raise cash in 2025 or 2026.</p>
<div class="lb-trans"><p>该公司还拥有强劲的资产负债表，使其无需筹集资金即可运营。其现金及等价物超过 1200 万美元。这意味着该公司可能需要在 2025 年或 2026 年筹集资金。</p>
</div><p>Still, I believe that Cassava Sciences is a high-risk company whose simufilam drug faces substantial risks ahead.</p>
<div class="lb-trans"><p>尽管如此，我认为 Cassava Sciences 是一家高风险公司，其 Simufilam 药物面临着重大风险。</p>
</div><h2>Cassava Sciences stock price analysis</h2>
<div class="lb-trans"><h2>Cassava Sciences 股价分析</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://invezz.com/wp-content/uploads/2024/07/Cassava-Sciences-stock-1024x570.png" alt="" original-src="https://invezz.com/wp-content/uploads/2024/07/Cassava-Sciences-stock-1024x570.png"/></p>
<p>SAVA chart by TradingView</p>
<div class="lb-trans"><p>TradingView 提供的 SAVA 图表</p>
</div><p>The weekly chart shows that the SAVA share price has been in a freefall in the past few years. On Friday, the stock moved below the key support at $12.33, its lowest swing in October 2023 and July 2022.</p>
<div class="lb-trans"><p>周线图显示，SAVA 股价在过去几年中一路下跌。上周五，股价跌破了 12.33 美元的关键支撑位，创下 2023 年 10 月和 2022 年 7 月的最低点。</p>
</div><p>Cassava Sciences’ share price has remained below the 50-week and 100-week Exponential Moving Averages (EMA). Therefore, the stock will likely continue falling as sellers target the key support at $10. This means that it could crash by about 20% from the current level. A drop below that point could drop to the key point at $6.40.</p>
<div class="lb-trans"><p>Cassava Sciences 的股价一直低于 50 周和 100 周指数移动平均线（EMA）。因此，股价可能会继续下跌，卖方将瞄准 10 美元的关键支撑位。这意味着它可能会从当前水平下跌约 20%。跌破该点可能会下跌至 6.40 美元的关键点。</p>
</div><p>The post Cassava Sciences stock forecast: is it safe to buy the SAVA dip? appeared first on Invezz</p>
<div class="lb-trans"><p>本文最初发表于 Invezz，转载请注明出处。</p>
</div>

Cassava Sciences 股票预测：现在买入 SAVA 的低点是否安全？